{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:27Z","timestamp":1793831307951,"version":"4.6.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"42","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014941","name":"Cytokinetics, Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014941","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Adolph Hutter Professorship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical characteristics and baseline concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I (hs-cTnI), and to evaluate the effect of treatment with aficamten on biomarker concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cardiac biomarkers were measured at baseline and serially throughout the study. Regression analyses determined predictors of baseline NT-proBNP and hs-cTnI concentrations, and evaluated whether early changes in these biomarkers relate to later changes in left ventricular outflow tract gradient (LVOT-G), other echocardiographic measures, health status, and functional capacity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline concentration of NT-proBNP was associated with LVOT-G and measures of diastolic function, while hs-cTnI was associated with left ventricular thickness. Within 8 weeks of treatment with aficamten, NT-proBNP was reduced by 79% (95% confidence interval 76%\u201383%, P &amp;lt; .001) and hs-cTnI by 41% (95% confidence interval 32%\u201349%, P &amp;lt; .001); both biomarkers reverted to baseline after washout. Reductions in NT-proBNP and hs-cTnI by 24 weeks were strongly associated with a lowering of LVOT-G, improvement in health status, and increased peak oxygen uptake. N-Terminal pro-B-type natriuretic peptide reduction strongly correlated with the majority of improvements in exercise capacity. Furthermore, the change in NT-proBNP by Week 2 was associated with the 24-week change in key endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>N-Terminal pro-B-type natriuretic peptide and hs-cTnI concentrations are associated with key variables in obstructive hypertrophic cardiomyopathy. Serial measurement of NT-proBNP and hs-cTnI appears to reflect clinical response to aficamten therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehae590","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T07:16:54Z","timestamp":1725175014000},"page":"4464-4478","source":"Crossref","is-referenced-by-count":32,"title":["Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial"],"prefix":"10.1093","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3208-470X","authenticated-orcid":false,"given":"Caroline J","family":"Coats","sequence":"first","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6390-6526","authenticated-orcid":false,"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Oregon Health & Science University , Portland, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-3487","authenticated-orcid":false,"given":"Roberto","family":"Barriales-Villa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Complexo Hospitalario Universitario A Coru\u00f1a, INIBIC, CIBERCV-ISCIII , A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[{"name":"UCSF Adult Cardiac Echocardiography Lab, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas Marshall","family":"Brinkley","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Vanderbilt Heart & Vascular Institute , Nashville, TN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-9218","authenticated-orcid":false,"given":"Brian L","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-6077","authenticated-orcid":false,"given":"Albert","family":"Hagege","sequence":"additional","affiliation":[{"name":"D\u00e9partement de Cardiologie, Assistance Publique H\u00f4pitaux de Paris, H\u00f4pital Europ\u00e9en Georges-Pompidou , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila M","family":"Hegde","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7334-7924","authenticated-orcid":false,"given":"Carolyn Y","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J","family":"Kulac","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M Y","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow , Glasgow ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-3853","authenticated-orcid":false,"given":"Martin S","family":"Maron","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Lahey Hospital and Medical Center , Burlington, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Meyer Children\u2019s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico , Florence ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9669-8495","authenticated-orcid":false,"given":"Anjali T","family":"Owens","sequence":"additional","affiliation":[{"name":"Center for Inherited Cardiovascular Disease, Division of Cardiovascular Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-9316","authenticated-orcid":false,"given":"Jacob","family":"Tfelt-Hansen","sequence":"additional","affiliation":[{"name":"Section of Forensic Genetics, Department of Forensic Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]},{"name":"Department of Cardiology, Copenhagen University Hospital Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-9016","authenticated-orcid":false,"given":"Hugh","family":"Watkins","sequence":"additional","affiliation":[{"name":"Radcliffe Department of Medicine, University of Oxford , Oxford ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9182-275X","authenticated-orcid":false,"given":"Daniel L","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2189-1474","authenticated-orcid":false,"given":"Stephen B","family":"Heitner","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5469-1287","authenticated-orcid":false,"given":"Stuart","family":"Kupfer","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-5759","authenticated-orcid":false,"given":"Fady I","family":"Malik","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Meng","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Wohltman","sequence":"additional","affiliation":[{"name":"Clinical Research, Cytokinetics, Incorporated , South San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8338-1798","authenticated-orcid":false,"given":"James L","family":"Januzzi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School , 55 Fruit Street, Boston, MA 02114 ,","place":["USA"]},{"name":"Clinical Trials, Baim Institute for Clinical Research , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"key":"2024110809202183800_ehae590-B1","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1016\/j.jacc.2016.08.079","article-title":"Clinical and mechanistic insights into the genetics of cardiomyopathy","volume":"68","author":"Burke","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2024110809202183800_ehae590-B3","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Writing Committee Members","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B4","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/eht070","article-title":"Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy","volume":"34","author":"Coats","year":"2013","journal-title":"Eur Heart J"},{"key":"2024110809202183800_ehae590-B5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1016\/j.jacc.2013.04.004","article-title":"B-type natriuretic peptide and survival in hypertrophic cardiomyopathy","volume":"61","author":"Geske","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B6","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1002\/ehf2.14073","article-title":"Blood-based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta-analysis","volume":"9","author":"Jansen","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2024110809202183800_ehae590-B7","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1253\/circj.cj-10-0782","article-title":"Combined measurements of cardiac troponin I and brain natriuretic peptide are useful for predicting adverse outcomes in hypertrophic cardiomyopathy","volume":"75","author":"Kubo","year":"2011","journal-title":"Circ J"},{"key":"2024110809202183800_ehae590-B8","doi-asserted-by":"publisher","first-page":"e027618","DOI":"10.1161\/JAHA.122.027618","article-title":"Circulating biomarkers in hypertrophic cardiomyopathy","volume":"11","author":"Matthia","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2024110809202183800_ehae590-B9","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.jacc.2019.08.1057","article-title":"Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry","volume":"74","author":"Neubauer","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B10","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jchf.2023.04.018","article-title":"Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: heart failure state-of-the-art review","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2024110809202183800_ehae590-B11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","article-title":"Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort","volume":"12","author":"Rader","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024110809202183800_ehae590-B12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"2024110809202183800_ehae590-B14","doi-asserted-by":"publisher","first-page":"14142","DOI":"10.1021\/acs.jmedchem.1c01290","article-title":"Discovery of aficamten (CK-274), a next-generation cardiac myosin inhibitor for the treatment of hypertrophic cardiomyopathy","volume":"64","author":"Chuang","year":"2021","journal-title":"J Med Chem"},{"key":"2024110809202183800_ehae590-B15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jchf.2023.10.004","article-title":"Exercise capacity in patients with obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM baseline characteristics and study design","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2024110809202183800_ehae590-B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-19425-7","volume-title":"Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"2024110809202183800_ehae590-B17","doi-asserted-by":"publisher","first-page":"e979","DOI":"10.1002\/ctm2.979","article-title":"Cardiac troponin T in extracellular vesicles as a novel biomarker in human cardiovascular disease","volume":"12","author":"Lennon","year":"2022","journal-title":"Clin Transl Med"},{"key":"2024110809202183800_ehae590-B18","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3390\/life12081241","article-title":"Association of NT-proBNP and hs-cTnT with imaging markers of diastolic dysfunction and focal myocardial fibrosis in hypertrophic cardiomyopathy","volume":"12","author":"Chevalier","year":"2022","journal-title":"Life (Basel)"},{"key":"2024110809202183800_ehae590-B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B20","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Randomized trial of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2024110809202183800_ehae590-B21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2024110809202183800_ehae590-B22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ejhf.1771","article-title":"Sex-related differences in contemporary biomarkers for heart failure: a review","volume":"22","author":"Suthahar","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2024110809202183800_ehae590-B23","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2024110809202183800_ehae590-B24","doi-asserted-by":"publisher","first-page":"e008410","DOI":"10.1161\/CIRCHEARTFAILURE.120.008410","article-title":"Association between angiotensin receptor-neprilysin inhibition, cardiovascular biomarkers, and cardiac remodeling in heart failure with reduced ejection fraction","volume":"14","author":"Murphy","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2024110809202183800_ehae590-B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2024.02.020","article-title":"Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, cohort 4","author":"Masri","year":"2024","journal-title":"J Card Fail"},{"key":"2024110809202183800_ehae590-B26","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehae590\/58968956\/ehae590.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/42\/4464\/60538268\/ehae590.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/45\/42\/4464\/60538268\/ehae590.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T09:21:44Z","timestamp":1731057704000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/45\/42\/4464\/7745563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":26,"journal-issue":{"issue":"42","published-online":{"date-parts":[[2024,9,1]]},"published-print":{"date-parts":[[2024,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehae590","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11,7]]},"published":{"date-parts":[[2024,9,1]]}}}